Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedSep 05, 2025
DataAggregated Company Financials
Companies548
  • 7D1.3%
  • 3M6.8%
  • 1Y-6.0%
  • YTD6.0%

Over the last 7 days, the Biotech industry has risen 1.3%, driven by gains from AbbVie of 2.4%. In the past year, the industry is down 6.0%. As for the next few years, earnings are expected to grow by 26% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 06 Sep 2025US$1.1tUS$163.5b-US$18,341,252,720.1115.5x-58.6x6.6x
Mon, 04 Aug 2025US$1.0tUS$158.4b-US$20,947,422,497.0215.8x-48.4x6.4x
Wed, 02 Jul 2025US$927.2bUS$156.0b-US$23,839,320,142.0917.5x-38.9x5.9x
Fri, 30 May 2025US$914.8bUS$155.9b-US$23,981,521,247.8015.7x-38.1x5.9x
Sun, 27 Apr 2025US$783.3bUS$119.2b-US$31,074,126,492.8219.8x-25.2x6.6x
Tue, 25 Mar 2025US$827.0bUS$118.6b-US$36,869,226,191.9320.7x-22.4x7x
Thu, 20 Feb 2025US$842.4bUS$116.6b-US$36,830,915,932.5217.4x-22.9x7.2x
Sat, 18 Jan 2025US$943.3bUS$149.4b-US$26,286,132,923.6717.3x-35.9x6.3x
Mon, 16 Dec 2024US$991.8bUS$150.0b-US$26,493,336,471.9416.6x-37.4x6.6x
Wed, 13 Nov 2024US$1.1tUS$149.6b-US$27,274,668,753.1816.1x-40.4x7.4x
Fri, 11 Oct 2024US$885.7bUS$113.1b-US$35,992,841,232.3420.3x-24.6x7.8x
Sun, 08 Sep 2024US$873.8bUS$113.1b-US$35,668,533,175.3222.2x-24.5x7.7x
Tue, 06 Aug 2024US$1.2tUS$165.8b-US$32,345,907,600.2024.9x-37x7.2x
Thu, 04 Jul 2024US$1.1tUS$164.5b-US$27,946,912,225.8427.9x-40.1x6.8x
Sat, 01 Jun 2024US$1.1tUS$164.6b-US$26,677,227,566.3227.4x-41.6x6.7x
Mon, 29 Apr 2024US$1.1tUS$164.6b-US$27,372,800,636.0922.6x-39.1x6.5x
Wed, 27 Mar 2024US$1.2tUS$164.4b-US$23,792,606,116.0221.2x-48.8x7.1x
Fri, 23 Feb 2024US$1.2tUS$169.0b-US$20,212,652,991.5813.2x-57x6.8x
Sun, 21 Jan 2024US$1.4tUS$204.8b-US$22,506,538,466.0018.5x-63.3x7x
Tue, 19 Dec 2023US$1.4tUS$204.7b-US$22,117,247,361.0019.2x-61x6.6x
Thu, 16 Nov 2023US$1.2tUS$204.7b-US$22,143,559,902.0018.4x-55.1x6x
Sat, 14 Oct 2023US$1.3tUS$207.3b-US$13,141,713,262.0016.6x-96.4x6.1x
Mon, 11 Sep 2023US$1.3tUS$207.5b-US$12,633,744,533.0017.4x-101x6.1x
Wed, 09 Aug 2023US$1.3tUS$206.4b-US$12,500,248,802.0016.4x-101x6.1x
Fri, 07 Jul 2023US$1.1tUS$186.2b-US$16,056,868,924.0013.2x-69.5x6x
Sun, 04 Jun 2023US$1.1tUS$185.9b-US$16,014,255,509.0011.4x-71.1x6.1x
Tue, 02 May 2023US$1.2tUS$197.0b-US$6,677,740,450.0014x-175.7x6x
Thu, 30 Mar 2023US$1.1tUS$198.3b-US$4,280,712,821.0013.8x-266.8x5.8x
Sat, 25 Feb 2023US$1.1tUS$200.5b-US$3,797,679,065.0014.2x-295.4x5.6x
Mon, 23 Jan 2023US$1.2tUS$203.8bUS$1.8b14.4x655.9x5.7x
Wed, 21 Dec 2022US$1.2tUS$203.3bUS$1.6b14.6x704x5.7x
Fri, 18 Nov 2022US$1.1tUS$202.2bUS$1.2b14.7x921.2x5.5x
Sun, 16 Oct 2022US$1.0tUS$206.0bUS$5.4b15.6x194.3x5.1x
Tue, 13 Sep 2022US$1.1tUS$206.9bUS$5.9b15.8x185.7x5.3x
Price to Earnings Ratio

185.7x


Total Market Cap: US$1.1tTotal Earnings: US$5.9bTotal Revenue: US$206.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 37.9x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.5% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.008%
Healthcare0.72%
Biotech1.34%
Biotech1.34%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
UTHR United TherapeuticsUS$400.5231.4%
+US$4.3b		15.9%PE14.6x
ONC BeOne MedicinesUS$341.8011.7%
+US$3.9b		78.7%PS8.2x
ABBV AbbVieUS$212.561.0%
+US$3.8b		9.9%PE100.9x
BNTX BioNTechUS$112.4612.5%
+US$3.0b		25.0%PS8x
IONS Ionis PharmaceuticalsUS$61.2343.6%
+US$3.0b		30.6%PS10.3x

Latest News

ABBV
US$212.56
AbbVie
7D
1.0%
1Y
9.9%
INSM
US$145.10
Insmed
7D
6.6%
1Y
104.3%
IONS
US$61.23
Ionis Pharmaceuticals
7D
43.6%
1Y
30.6%
GILD
US$115.05
Gilead Sciences
7D
1.8%
1Y
46.2%

Global Healthcare Trends Will Expand Access To Advanced Therapies

Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.
SMMT
US$23.80
Summit Therapeutics
7D
-2.5%
1Y
90.4%
CYTK
US$53.01
Cytokinetics
7D
50.0%
1Y
-2.0%

Precision Medicine And Late-stage Trials Will Expand Global Reach

Upward revisions in analyst price targets for Cytokinetics reflect increased confidence in aficamten’s strong Phase 3 data, anticipated favorable FDA outcomes, and expanded commercial prospects, partially offset by concerns over possible REMS limitations and launch pacing, resulting in a higher consensus price target of $73.21. Analyst Commentary Bullish analysts highlight strong Phase 3 MAPLE-HCM and extension study data for aficamten, citing de-risked profile and high efficacy/safety, increasing their confidence ahead of regulatory decisions.
ONC
US$341.80
BeOne Medicines
7D
11.7%
1Y
78.7%

Oncology Trials And Global Expansion Will Unlock Future Markets

The consensus analyst price target for BeOne Medicines was raised to $363.30, primarily driven by strong Brukinsa Q2 sales, improved forward revenue guidance, and ongoing pipeline progress. Analyst Commentary Bullish analysts cite robust Q2 sales growth, particularly from Brukinsa in the US and EU, as the main driver for upward price target revisions.
UTHR
US$400.52
United Therapeutics
7D
31.4%
1Y
15.9%

Phase III Readouts Will Broaden Pulmonary And Regenerative Markets

United Therapeutics’ consensus price target has been raised from $380.57 to $399.90, reflecting heightened analyst optimism following positive Phase 3 TETON-2 Tyvaso IPF results that signal a multibillion-dollar sales opportunity and improved revenue outlook despite competitive and litigation risks. Analyst Commentary Bullish analysts increased price targets sharply following "surprisingly positive" Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis (IPF), citing clinically meaningful FVC benefit, strong statistical significance, and a competitive efficacy profile compared to pipeline peers.
SPRY
US$10.69
ARS Pharmaceuticals
7D
-16.9%
1Y
-9.0%

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Aug 28
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
REGN
US$573.38
Regeneron Pharmaceuticals
7D
-1.3%
1Y
-49.3%
AMGN
US$283.64
Amgen
7D
-1.4%
1Y
-11.5%
ZLAB
US$30.00
Zai Lab
7D
-6.9%
1Y
52.7%
BNTX
US$112.46
BioNTech
7D
12.5%
1Y
25.0%
CAI
US$34.85
Caris Life Sciences
7D
-9.2%
1Y
n/a
AKRO
US$44.72
Akero Therapeutics
7D
-4.3%
1Y
69.3%
TECX
US$17.27
Tectonic Therapeutic
7D
-32.5%
1Y
-5.5%